A gene editor that rewrites DNA gets its first patient
Prime Medicine, in Cambridge, Massachusetts, has given the first dose of a prime editor to a patient in a global clinical trial for Wilson disease. The infusion went in earlier this month, and the editor works directly on DNA inside liver cells 181.
Introduced in 2019, prime editing can swap single DNA letters, insert new genetic instructions or delete chunks, with minimal damage to the genome. In theory it could correct up to 89 percent of known disease-linked variants 181. The gene-editing treatment approved in 2024, Casgevy, edits blood stem cells outside the body instead. Last year a baby named KJ Muldoon got a custom base editor, a gentler relative of the original CRISPR cutter, and his symptoms eased within weeks 181.